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Background. Allergen-speciﬁc sublingual immunotherapy (SLIT) is considered a causal treatment of respiratory allergies.
Compliance to the SLIT is an important aspect for a positive clinical outcome. Study Aim. To evaluate if compliance with grass
Allergy Immunotherapy Tablet (AIT) can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-
container with a programmable daily acoustic alarm). Patients and Methods. 261 patients with grass allergy were enrolled and
randomized (1 : 1) to 1-year treatment with AIT (Grazax) using a CED (group A; n = 122) or without (Group B, n = 139).
Compliance was measured through tablet count at each visit. Results. The 12-month compliance, mean (SD), in group A was 83%
(21) and 83% (24) in group B. A total of 81% of patients reported a signiﬁcant clinical improvement of symptoms after treatment
in comparison with the previous year. No severe adverse reactions were observed in the study. Conclusion. Compliance to the
treatment with AIT administered for 12 consecutive months is in general good. The use of CED is not associated with a greater
compliance. AIT treatment was associated with a signiﬁcant clinical improvement in >80% of patients with a good tolerability and
safety proﬁle.
1.Introduction
Allergic rhinoconjunctivitis represents a global health prob-
lem aﬀecting 10 to 25% of the population [1]. Allergy to
grass pollen is one of the most common inhalant allergies
in the western world. In an unselected “healthy” population
ithasbeenfoundthat8to21%ofchildrenand13%ofadults
are sensitized to grass pollen [2]. In selected populations
of allergic subjects 44% are allergic to grass pollen [3].
Allergic rhinoconjunctivitis has been identiﬁed as one of the
main reasons for visits to primary care clinics, and although
usually not regarded as a severe disease it signiﬁcantly limits
the social life of the subject and aﬀects school learning
performance and work productivity [4]. Allergen-speciﬁc
immunotherapy is the practice of administering to allergic
patients increasing amount of allergen in order to obtain
hyposensitization [5]. Allergen-speciﬁc immunotherapy is
considered the only causal treatment of allergic diseases such
as allergic rhinitis asthma and insect venom allergy. The
purpose of allergen-speciﬁc immunotherapy is to expose the
patient to the allergen that causes the allergic symptoms, in
order to increase the tolerance to this allergen and reduce
symptoms [6]. Mechanisms of action of allergen-speciﬁc
immunotherapy are not so far clearly identiﬁed; however,
data are available that allergen-speciﬁc immunotherapy can
induce an increased production of allergen-speciﬁcIgG4 and
IL-10 [7]. Alternative mechanisms include immune devia-
tion in favour of TH1 responses and apoptosis and/or anergy
of antigen-speciﬁc T cells. Allergen-speciﬁc immunotherapy
exerts its beneﬁcial eﬀects over long periods (i.e., weeks or
months), and 3-4 years of treatment are required to obtain
a favourable clinical and immunological response [8]. The2 Journal of Allergy
treatment with allergen-speciﬁc immunotherapy is currently
administered as subcutaneous (s.c.) injections by specialists
and reduces the allergic symptoms considerably [9]. The
“standard”allergyvaccinationprogramrequiresanupdosing
period followed by a maintenance period of 3–5 years [10].
This implies that only a fraction of allergic subjects are actu-
ally oﬀered allergy vaccination despite the fact that allergen-
speciﬁc immunotherapy is the only treatment modality that
changes the natural cause of the allergic disease and thereby
prevents its exacerbation. The treatment modality is well
known as clinical application of Phleum pratense for s.c.
administration has been carried out during the past 30 years
in several European countries [11]. Allergen-speciﬁc sub-
lingual immunotherapy (SLIT) has gained wide acceptance
in many European countries and has raised the level of
interest in immunotherapy among practicing allergists
and primary care physicians. Large pivotal double-blind,
placebo-controlled, randomized clinical trials have con-
ﬁrmed the eﬃcacy and safety of SLIT. Allergen-speciﬁc
sublingual immunotherapy with grass products has also had
a widespread application—especially in Southern Europe
throughoutthe past 30 years[12]. The generalrecommenda-
tion today is to apply a higher than the accumulated dosage
applied subcutaneously. Grass allergy immunotherapy tablet
(AIT) (Grazax; ALK Denmark) has been developed for
allergen-speciﬁc immunotherapy [13]. Grazax is formulated
as an orodispersible tablet for sublingual use and contains
a standardised allergen extract derived from extraction and
puriﬁcation of the source material, Phleum pratense Timothy
grass pollen [14]. To obtain an optimal therapeutic response
with immunotherapy requires patients to be compliant with
the recommendations given by the physicians. Maximal
compliance can improve the patient’s condition and also
result in a reduction in drug costs [15]. Conversely, poor
compliance may result in the physicians adding in more
medicationstotreatthepatient’scondition,whichmaymake
the problem worse. Compliance to allergen-speciﬁc im-
munotherapy could be negatively inﬂuenced by several
factors such as: duration of treatment, side eﬀects, especially
in the initiation phase, and need to take medication also
outside the pollen season period when the patient in general
does not have any symptoms. Speciﬁc allergen SLIT is a
long-lasting home treatment that is directly managed by
patients and parents. Therefore, as allergen-speciﬁc SLIT is
self-managed at home without direct supervision, adequate
compliance with this administration route is important.
2. Study Aim
The primary objective of the trial was to evaluate if compli-
ance of once daily dosing with grass AIT in adult subjects
with grass-pollen-induced allergic rhinoconjunctivitis could
be increased by providing patients with compliance device
(Memozax) (Figure 2) given from the beginning of im-
munotherapy in comparison with patients without the
Memozax. Secondary endpoints of the trial were to evaluate
safety and tolerability of grass AIT treatment and ﬁnally
to evaluate the tolerability of the ﬁrst dose intake of AIT
and to evaluate after 48-week treatment with grass allergy
tablet tablets the impact on symptom score and patient’s
acceptance in comparison with previous pollen seasons.
3. Patients andMethods
3.1. Study Design. This was a 23-centre, single-dose, ran-
domized parallel-group, open-label, controlled trial.
3.2. Patients Selection. A total of 240 subjects were planned
for enrolment. Enrolled patients were adult (>18 years), men
or women, suﬀering from mild or moderate/severe grass-
pollen-induced allergic rhinoconjunctivitis. A total of 261
patientswerescreened,enrolled,andrandomizedto48-week
treatment with AIT using the compliance aid device (Mem-
ozax) or 48-week treatment with AIT without the compli-
ance device. The screening phase lasted 1 week. Therefore
the total study duration was 49 weeks. All enrolled patients
were treated with one tablet of AIT daily for 48 weeks.
3.3. Inclusion and Exclusion Criteria. Subjects were selected
from the outpatient population of allergy clinics in Italy.
Subject selection was based on the following criteria. Inclu-
sion criteria were as follows: subjects, men and women >18
years of age and <65 years; suﬀering from mild or moder-
ate/severe grass-pollen-induced rhinoconjunctivitis (accord-
ing to ARIA Guidelines [16]) and with a positive SPT for
Phleum pratense extract (≥3mm); every patient should
give a written informed consent to participate in the trial.
Exclusion criteria at randomization were as follows: current
symptoms of, or treatment for, upper respiratory tract
infection,acutesinusitis, acuteotitis media,orotherrelevant
infectious processes; history of emergency visit or admission
for asthma in the previous 12 months; use of an investi-
gational drug within 30 days prior to screening; previous
treatment by immunotherapy with grass pollen allergen;
previous treatment by immunotherapy with other allergen
than grass pollen allergen; within the previous 5 years; his-
tory of anaphylaxis, including anaphylactic food allergy, bee
venom anaphylaxis, exercise anaphylaxis, or drug-induced
anaphylaxis; or history of angioedema.
3.4. Therapeutic Regimen. The treatment used was Grazax
oral lyophilisate 75,000 SQ-T tablets (Phleum pratense grass
pollen allergen extract). The daily dose was one tablet,
which should preferably be taken in the morning. The tablet
was placed under the tongue and swallowing should be
avoidedforoneminute.Eatinganddrinkingwasnotallowed
within ﬁve minutes after trial medication intake. The same
drug taking instructions were given to both study groups
(randomized to Memozax or not). Concomitant medica-
tions were all medications (including rhinoconjunctivitis
medications and asthma treatments) being continued by
a subject on entry to the trial and all medications given
in addition to the treatment during the trial. All concomitant
medicationsshouldhavebeendocumentedintheCRF(trade
name as appropriate). Further, each change in concomitant
treatment (e.g., new treatment, discontinuation of treat-
ment,andchangeindosage/routine)duringthetrialmustbeJournal of Allergy 3
documented in the same way. At each visit, the investigator
asked the subject about concomitant medications. Any con-
comitant medication was recorded in the subject’s notes as
sourcedatadocumentationandintheCRF.Theinvestigators
were instructed to store the drug in an appropriate, secure
area (e.g., locked cabinet) and to store it according to the
conditions speciﬁed on the labels. The investigator should
have to maintain an accurate record of the shipment and
dispensing of trial medication in a drug accountability log,
a copy of which was given to ALK-Abell´ o at the end of the
trial.Anaccuraterecordofthedateandamountoftrialmed-
ication dispensed to each subject was available for inspection
at any time. The ﬁrst dose was taken in the clinic and the
subject stayed in the clinic for 60 minutes for observation.
The ﬁrst dose tolerability was recorded in the CRF. The fol-
lowingdosesweretakenathome.Theexperimentaldrugwas
supplied in blister cards containing 10 tablets each. The
blister cards were packed in visit speciﬁc boxes.
3.5. Randomization Procedures. Between October 2007 and
February 2008 a total of 240 subjects were planned to receive
grass AIT as an oral lyophilisate once daily. The subjects
were randomized (1:1) using a randomization list with
half the subjects planned to receive the compliance device
and half not to receive the device. Subjects were identiﬁed
by ascending 2-digit randomization numbers, plus 2-digit
referring to the centre and entered in the Case Report Form.
When a subject was randomized in the trial he/she had
to be assigned the lowest available randomization number
for that centre. The randomization number was a 5-digit
number where the two ﬁrst digits gave a center code. Grass
allergen tablet treatment was provided at the screening/
randomization visit together with the Memozax, according
to the randomization list. In all enrolled patients treatment
started at least 3 months before the pollen season of 2008.
3.6. Compliance Evaluation. The primary outcome of the
study was the evaluation and comparison of compliance
in the two groups (with Memozax and without Memozax)
evaluatedwithpillcountatvisits3(week2),4(week24),and
5 (week 48) calculated in the following manner: number of
pill eﬀectively taken/number of pill to be taken ×100. Sub-
jects were instructed to return all residual and unused trial
medications and all empty packaging at every visit. Compli-
ance was assessed by tablet counts.
3.7. Secondary Endpoints of the Trial. Other eﬃcacy assess-
mentwastoevaluateafter48weeksoftreatmentwithGrazax
tablets the impact on quality of life, symptom score, and
patient’s acceptance in comparison with previous pollen
seasons. This was evaluated, globally, through a 10cm VAS
scale(0 = bigimprovement,5 = notimprovement,and10 =
worsening of symptoms). The safety assessments included
recording of all adverse events (AEs) and serious adverse
events (SAEs) ﬁndings from physical examinations and vital
signs.
3.8. Conduction of the Trial. This trial was conducted in
compliance with the principles of Good Clinical Practice.T h e
trialwasmonitoredaccordingtoSponsorCompanystandard
operating procedures for the monitoring of clinical studies
and other trial-speciﬁc procedures. The trial was monitored
by the sponsor or its delegate by means of on-site visits,
telephone calls, and regular inspection of the CRFs with
suﬃcient frequency (every 8–12 weeks) to verify the follow-
ing: subject enrolment; compliance with the protocol; the
completeness and accuracy of data entered in the CRFs by
veriﬁcation against original source documents; compliance
in the use of IMP; drug accountability; recording of adverse
events.
3.9. Statistical Methods and Sample Size Calculation. All
statistical analyses were carried out by SPSS statistical Pack-
age software. The following analysis set was deﬁned in the
protocol: full-analysis set (FAS), this consists of all subjects
randomized following the intent-to-treat (ITT) ICH princi-
ple.TheFASwastheonlyanalysisset.Ascientiﬁcpublication
has shown that compliance to SLIT treatment >90% without
any device system was registered in 75% of treated patients.
Inthisstudyitwashypothisedthatthegroupofpatientswith
the Memozax device should have a better compliance (a rela-
tive increase of 15% or more) in comparison with the group
without the aid device (86% of patients with a compliance
of 90% or more in the Memozax group versus a 75% in the
group without the Memozax). A minimum of 120 subjects
per group, with an alfa error of 0.05 and a power of 80%,
therefore should be enrolled in the trial. Actually a total
of 261 patients were enrolled in this trial. The comparison
between the two groups was analyzed using the ANOVA test.
The comparison of percentage of patients with a compliance
<90% and >90% between the two groups was performed
with the Fisher exact test.
4. Results
A ﬂowchart of subjects disposition is presented in Figure 1.
The subject demographic values, smoking history, and
allergy disease history at baseline are summarised in Table 1.
There were no major baseline diﬀerences between the two
groups.Itistonotethat73%oftheenrolledpatientssuﬀered
from moderate/severe allergic rhinoconjunctivitis. A total of
50 patients (25 in both groups) also reported asthma (19%
of FAS population). Monosensitive patients (subjects with
SPT positive only for grass extracts) were 68 (26%) and
multisensitive patients (subjects with also at least one
positive SPT toward nongrass allergens) were 193 (74%).
4.1. Primary Endpoint: Compliance. The overall mean com-
pliance rate was 91.3% (median 97%) for the subjects
with complete compliance data from visit 3 to visit 5. The
primary endpoint in this trial was a comparison of the
degree of compliance in the two groups (Memozax and non-
Memozax). For this purpose compliance was categorised as
excellent (≥90%) or less excellent (<90%). The proportion
of subjects with excellent compliance in the Memozax group
was similar (79%) to that in the non-Memozax group (78%)
(Table 2). The diﬀerence was not statistically signiﬁcant (P =
0.5).4 Journal of Allergy
Table 1: Patients demographic characteristics at baseline.
Treatment Group Grazax+
Memozax
Grazax−
Memozax
Number of subjects 139 122
Age (years) #
N 139 122
Mean (SD) 32 (9) 33 (10)
Median 32.0 33.0
Min-Max 19–60 18–63
Sex
N 139 22
Men 75 (54%) 74 (60%)
Women 64 (46%) 48 (40%)
Allergic rhinitis
Mild 37 (26%) 33 (27%)
Moderate/severe 102 (74%) 89 (73%)
Monosensitive subjects 32 (23%) 36 (29%)
Polysensitive subjects 107 (77%) 86 (71%)
Asthma (Gina class: I–III)
N 25 (18%) 25 (20%)
N: Number of subjects; (%): Percent of subjects.
Table 2: Excellent compliance versus less excellent compliance.
Treatment Group
Grazax+ Grazax−
Memozax Memozax
N (%) N (%)
Number of subjects 139 122
Primary analysis no.
N 113 99
Excellent
compliance (≥90%)
90 (79%) 78 (78%)
Less excellent
compliance (<90%)
23 (21%) 21 (22%)
N: Number of subjects; (%): Percent subjects.
4.2. Secondary Endpoints: Clinical Eﬃcacy, Tolerability, and
Safety. Other eﬃcacy assessment was to evaluate after 48
weeks of treatment with Grazax tablets the impact on quality
of life, symptom score, and patient’s acceptance in com-
parison with previous pollen seasons. This was evaluated,
globally, through a 10cm VAS scale (0 = big improvement,
5 = not improvement, and 10 = worsening of symptoms)
which was performed by the patient. At visit 5 the mean VAS
score was 2.4 ± 1.8 showing a general clinical improvement.
The percentage of patients with a VAS score = or >5( n o -
diﬀerence/worsening in comparison with the previous sea-
son) was 19%. Therefore 81% of patients reported a clinical
improvement of symptoms after treatment with Grazax in
comparison with the previous year. Clinical eﬃcacy was
comparable both in monosensitized patients (68 out of 261:
26%) and in multisensitized subjects (193 out of 261: 74%).
Investigator Global Clinical evaluation of 48-week treatment
with Grazax was good/very good: 85%; suﬃcient: 9%; not
261 screened
261 enrolled
122 randomised to
Grazax no Memozax
139 randomised to
Grazax + Memozax
99 completed 113 completed
26 withdrawn 23 withdrawn
Figure 1: GT17 study ﬂow.
Figure 2: The compliance device (Memozax) used in the trial.
good: 6%. The percentage of subjects who reported adverse
events (AEs) in each of the two groups was almost similar,
14% in the Memozax group and 11% in the non-Memozax
group. A total of 63 AEs (78%) reported were judged
as probably or possibly related to immunotherapy by the
investigator,while14reportedAEswerejudgedasunlikelyor
not related to allergy tablet treatment. For 2 AEs, the inves-
tigator did not report the causality. The majority of AEs (71
out of 79: 90%) were either mild or moderate, with only 4%
(absolute number: 3) of AE reported as severe AE (mouth
itching). No serious adverse events were observed in the
study.
5. Discussion
Allergen-speciﬁc immunotherapy is the only causative treat-
ment of several allergy diseases. The main feature of this
therapeuticapproachisitscapacitytomodifythenaturalhis-
tory of the disease, reducing the development of asthma and
newsensitizationsafter3-4yearsoftreatment[17].Adequate
compliance to allergen-speciﬁc SLIT is, however, mandatory
in order to obtain these results.
This study trial investigated the compliance of 48-week
grass allergy tablet treatment in two groups of subjects, one
issued with the Memozax compliance device and the other
not issued with the device. Overall compliance with grassJournal of Allergy 5
AIT was high (>90%). The compliance rate in the Memozax
group was slightly higher (91.7%) than that in the non-
Memozax group (90.3%), but the diﬀerence was not statis-
tically signiﬁcant. A total of 79% of the patients in the Mem-
ozax group who completed the trial had a compliance >90%.
In the group without Memozax this percentage was 78%. In
the global evaluation, a total of 81% of patients reported
an improvement of symptoms after treatment with grass
AIT, evaluated through a 10cm VAS in comparison with the
previous season. Investigators evaluated the eﬃcacy of treat-
ment as good or very good in 85% of patients. In this trial
clinical eﬃcacy was of similar extent both in monosensitive
and polysensitive patients. This is a strong indication that
treatment with grass is eﬀective in relieving these symptoms,
and it is in line with results from previous grass AIT
trials. The safety proﬁle seen in this trial reﬂects the overall
good tolerance to grass allergen tablet treatment [18]. In this
study no serious adverse events or deaths were observed.
In conclusion compliance to the treatment with grass AIT
administered every day is in general high. In this speciﬁc
clinical setting, the use of electronic devices is not associated
with a greater compliance. In addition this trial supports the
safety, tolerability, and eﬃcacy proﬁle observed in previous
trials of this grass allergy immunotherapy tablet in grass
allergic patients.
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